<?xml version="1.0" encoding="utf-8"?>
<Journal>
<Journal-Info>
<name>International Journal of Pharma and Bio Sciences</name>
<website>ijpbs.net</website>
<email>editorijpbs@rediffmail.com (or) editorofijpbs@yahoo.com (or) prasmol@rediffmail.com</email>
</Journal-Info>
<article>
<article-id pub-id-type='other'>10.22376/ijpbs.2019.10.1.p1-12</article-id>
<issue_number>Volume 2 Issue 4</issue_number>
<issue_period>2011 (October - December)</issue_period>
<title>Pharmacovigilance </title>
<abstract> lessThan b greaterThan  lessThan i greaterThan Introduction lessThan /i greaterThan  lessThan /b greaterThan  India has more than half a million qualified doctors and 15,000 hospitals having bed strength of 6,24,000 . Many new drugs are being introduced in our country. The development of a better system of reporting ADRs has been recommended as a top priority action to prevent ADRs and ADEs. According to WHO Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects and any other drug related problem.  lessThan b greaterThan  lessThan i greaterThan Nature of Work lessThan /i greaterThan  lessThan /b greaterThan  The ADR monitoring centre will prepare a plan and educate the pharmacovigilance staff with regard to data collection and verification, interpreting and coding of adverse reaction description, coding of drugs, case causality assessment, signal detection and risk management.The pharmacovigilance centre will conduct the seminars and workshops to educate and train all the healthcare professionals, who are the source of information in pharmacovigilance,  lessThan b greaterThan  lessThan i greaterThan Conclusion lessThan /i greaterThan  lessThan /b greaterThan  Greater integration of pharmacovigilance into clinical practice is still needed. Hence, active participation of all the healthcare professionals is very important to make pharmacovigilance, a successful national programme.</abstract>
<authors>Janaki.R.Torvi And Rajesh Hunashal</authors>
<keywords>Pharmacovigilance; Central drugs standard control organization; WHO aims; Adverse drug reaction monitoring; National pharmacovigilance policy</keywords>
<pages>95-103</pages>
</article>
</Journal>
